LEIDOS AUSTRALIA PARTNERS WITH KEY AUSTRALIAN TEAMMATES FOR JP2060 PHASE 4 BID
|(Canberra, Australia), Sep 23, 2019 – Today, Leidos Australia announced Australian companies MediRecords, Coviu, and Nous as core partners for its Joint Project 2060 (JP2060) Phase 4 team. The Leidos-led team will provide a modern, intuitive, patient-centric and secure health knowledge management system that supports the delivery of health services to the Australian Defence Force (ADF).
“Leidos has created an exceptional team to deliver this critical capability to the ADF,” said Christine Zeitz, Chief Executive for Leidos Australia. “This includes partnering with leading Australian SMEs, within the health sector, who we will further support through our Global Supply Chain Program.”
The JP2060 partnership brings together healthcare experts from MediRecords, providing the primary and allied health care solutions; Coviu, providing the telemedicine capability; and Nous, leading the organisational change management to support the delivery of business transformation.
Leidos previously announced working with Cerner and Henry Schein, who are part of the Leidos Partnership for Defense Health. In 2015, the partnership was awarded a contract by the United States Department of Defense to deliver the MHS GENESIS solution, an electronic health record and care delivery system designed to transform the delivery of care for nearly 10 million service personnel and their families. The MHS GENESIS system is expected to be fully deployed across the U.S. military health system by the end of 2023. In Australia, Cerner is currently delivering electronic health solutions to public and private health clinics across New South Wales, Victoria, Queensland and South Australia.
JP2060 Phase 4 provides an opportunity to apply lessons learned from the implementation of MHS GENESIS directly to the Defence project. Leidos has recognised the different needs of the ADF and developed a team to deliver a robust, tested solution that best supports the ADF today and into the future.